Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL465792 | 0.87 | CCR2 (0.42) | CCR2LCKSCN9ANR3C2CHRNB2 | |
| SCHEMBL30396325 | 0.87 | CCR2 (0.42) | CCR2LCKSCN9ANR3C2CHRNB2 | |
| SCHEMBL4076010 | 0.87 | CHRNB2 (0.51) | CCR2LCKSCN9ANR3C2CHRNB2 | |
| SCHEMBL1022260 | 0.86 | GLS (0.42) | CCR2LCKSCN9ANR3C2CHRNB2 | |
| SCHEMBL21198393 | 0.86 | CCR2 (0.42) | CCR2LCKSCN9ANR3C2CHRNB2 | |
| SCHEMBL29988292 | 0.86 | GLS (0.42) | CCR2LCKSCN9ANR3C2CHRNB2 | |
| SCHEMBL2827164 | 0.86 | GLS (0.42) | CCR2LCKSCN9ANR3C2CHRNB2 | |
| SCHEMBL6681771 | 0.86 | CCR2 (0.42) | CCR2LCKSCN9ANR3C2CHRNB2 | |
| SCHEMBL29394473 | 0.85 | LCK (0.47) | LCKMEN1NPC1GAARAB9A | |
| SCHEMBL20098837 | 0.84 | CDK5 (0.44) | CCR2LCKSCN9ANR3C2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | claimed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | claimed |
| US-12492183-B2 | Tetrahydroquinazoline derivatives as selective cytotoxic agents | MERCK SHARP & DOHME LLC (US) | 2025-12-09 | — | — | US | disclosed |
| US-20240043402-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME LLC (US) | 2024-02-08 | — | — | US | disclosed |
| WO-2022213980-A1 | TYK2 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2022-10-13 | — | — | WO | disclosed |
| WO-2022125412-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125412-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-2546235-B1 | PROCESS FOR PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS | NIPPON SODA CO (JP) | 2019-05-22 | — | — | EP | disclosed |
| US-10287243-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2018-07-05 | — | — | US | disclosed |
| WO-2013059587-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013059587-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| CN-103003252-A | Process for the preparation of 5-substituted 1-alkyltetrazolyl oxime derivatives | BAYER IP GMBH | 2013-03-27 | — | — | CN | disclosed |
| EP-2557078-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND METHOD FOR PRODUCING SAME | Nippon Soda Co., Ltd. (JP) | 2013-02-13 | — | — | EP | disclosed |
| US-20130023664-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND METHOD FOR PRODUCING SAME | NIPPON SODA CO., LTD. (JP) | 2013-01-24 | — | — | US | disclosed |
| EP-2546235-A1 | PROCESS FOR PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS | Nippon Soda Co., Ltd. (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20130005981-A1 | PROCESS FOR PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS | NIPPON SODA CO., LTD. (JP) | 2013-01-03 | — | — | US | disclosed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082566-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492183-B2 | Tetrahydroquinazoline derivatives as selective cytotoxic agents | ACIN1, CD4, NFATC1 | CCR2 2422/4885LCK 443/4885SCN9A 3743/4885 |
| US-20130005981-A1 | PROCESS FOR PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS | BPGM, TST, BET1 | CCR2 4493/4885LCK 2456/4885SCN9A 2089/4885 |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | CCR2 3/4885LCK 457/4885SCN9A 2926/4885 |
| US-20240043402-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | ACIN1, CD4, NFATC1 | CCR2 2422/4885LCK 443/4885SCN9A 3743/4885 |
| US-20130023664-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND METHOD FOR PRODUCING SAME | NOS1, NOS2, NOS3 | CCR2 3556/4885LCK 2739/4885SCN9A 772/4885 |
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CCR2 3736/4885LCK 2586/4885SCN9A 3495/4885 |
| US-10287243-B2 | Sulfur derivatives as chemokine receptor modulators | CX3CR1, CXCR2, CCR2 | CCR2 3/4885LCK 457/4885SCN9A 2926/4885 |
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | CX3CR1, CXCR2, CCR2 | CCR2 3/4885LCK 457/4885SCN9A 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.